[A case of CA19-9 producing transitional cell carcinoma of the ureter effectively responsive to combination chemotherapy].

Abstract

We report a case of CA19-9 producing transitional cell carcinoma of the right ureter effectively responsive to combination chemotherapy (methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) regimen) in a 53-year-old woman. The maximum level of serum CA19-9 showed 3,000 U/ml and clinical staging of the tumor was T4 N3 M0. Marked regression of the tumor was identified by computed tomographic scan and the level of serum CA19-9 returned to the normal range after 3 courses of M-VAC therapy. Right total nephro-ureterectomy and partial cystectomy was done and the surgical specimen revealed no viable tumors. She is alive without evidence of local recurrence or metastasis at 6 months after resection. The serum CA19-9 level was useful for monitoring the clinical course.

• Authors: S Kanai, Y Takagi
• Journal: Hinyokika kiyo. Acta urologica Japonica (Hinyokika Kiyo) Vol. 38 Issue 11 Pg. 1253-6 (Nov 1992) ISSN: 0018-1994 [Print] Japan
• PMID: 1485576 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Antigens, Tumor-Associated, Carbohydrate
• Biomarkers, Tumor
• Vinblastine
• Doxorubicin
• Cisplatin
• Methotrexate

Topics

• Antigens, Tumor-Associated, Carbohydrate (biosynthesis, blood)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Biomarkers, Tumor (blood)
• Carcinoma, Transitional Cell (diagnosis, drug therapy)
• Chemotherapy, Adjuvant
• Cisplatin (administration & dosage)
• Doxorubicin (administration & dosage)
• Female
• Humans
• Methotrexate (administration & dosage)
• Middle Aged
• Tomography, X-Ray Computed
• Ureter (surgery)
• Ureteral Neoplasms (diagnosis, drug therapy)
• Vinblastine (administration & dosage)